Authors
Dr. Jayakumar B, DM., DNB (Cardiology), Consultant Cardiologist1
1Thankam Hospital, Palakkad
Abstract
Tirofiban is a peptidomimetic (nonpeptide) platelet glycoprotein IIb/IIIa inhibitor. Clinical studies have shown that tirofiban plus heparin is more effective than heparin alone in patients with acute coronary syndromes. Tirofiban has also been shown to be effective in reducing ischemic complications associated with percutaneous coronary intervention. Tirofiban (in combination with aspirin, clopidogrel and heparin) is indicated for use in patients undergoing PCI as well as for the treatment of unstable angina or non-Q-wave myocardial infarction.
Tirofiban is a competitive inhibitor of glycoprotein (GP) IIb/IIIa preventing the binding of fibrinogen, von Willebrand factor (vWF), and other adhesive ligands to the GP IIb/IIIa receptor on activated platelets.
Tirofiban is administered intravenously. The recommended regimen of 0.4 mcg/kg/min IV for 30 minutes followed by 0.1 mcg/kg/min IV thereafter produces a peak tirofiban plasma concentration that is similar to the steady state concentration during the infusion.